v3.25.2
Segment Information - Schedule of Segment Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
Revenues $ 3,181   $ 19,875   $ 8,573 $ 26,346
Research and development 32,807   38,654   69,249 76,719
Other segment expenses [1] 9,227   6,772   18,053 13,092
Net loss (38,853) $ (39,876) (25,551) $ (37,914) (78,729) (63,465)
TNG462 direct program expenses - R&D [Member]            
Segment Reporting Information [Line Items]            
Research and development 5,577   3,957   11,038 9,043
TNG456 direct program expenses - R&D [Member]            
Segment Reporting Information [Line Items]            
Research and development 1,646   0   2,970 0
TNG260 direct program expenses - R&D [Member]            
Segment Reporting Information [Line Items]            
Research and development 1,809   3,763   3,539 5,999
TNG961 direct program expenses - R&D [Member]            
Segment Reporting Information [Line Items]            
Research and development 1,572   0   3,793 0
TNG908 direct program expenses - R&D [Member]            
Segment Reporting Information [Line Items]            
Research and development [2] 1,235   3,260   2,947 7,518
TNG348 direct program expenses - R&D [Member]            
Segment Reporting Information [Line Items]            
Research and development [3] 0   1,641   0 4,941
Discovery direct program expenses - R&D [Member]            
Segment Reporting Information [Line Items]            
Research and development 2,709   7,514   7,388 13,025
Personnel-related expenses - R&D [Member]            
Segment Reporting Information [Line Items]            
Research and development 12,834   13,108   26,684 25,906
Facilities and Other Related Expenses - R&D [Member]            
Segment Reporting Information [Line Items]            
Research and development $ 5,425   $ 5,411   $ 10,890 $ 10,287
[1] Other segment expenses included in Segment net loss includes general and administrative expense, interest income, other income and provision for income taxes.
[2] In November 2024, we announced we stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization. Expenses beyond November 2024 related to previously enrolled patients and close-out clinical trial costs.
[3] In May 2024, we announced the discontinuation of TNG348, a USP1 inhibitor, due to toxicity observed in the dose escalation portion of our Phase 1/2 clinical trial. Expenses beyond May 2024 related to close-out clinical trial costs.